Dr Laura Flight

All publications

Journal articles

• Wason JMS, Dimairo M, Biggs K, Bowden S, Brown J, Flight L, Hall J, Jaki T, Lowe R, Pallmann P , Pilling MA et al (2022) Practical guidance for planning resources required to support publicly-funded adaptive clinical trials. BMC Medicine, 20(1). View this article in WRRO
• Flight L & Julious SA (2022) Practical guide to sample size calculations: Installation of the app SampSize.. Pharm Stat.
• Flight L, Julious S, Brennan A & Todd S (2021) Expected value of sample information to guide the design of group sequential clinical trials. Medical Decision Making.
• Wilson N, Biggs K, Bowden S, Brown J, Dimairo M, Flight L, Hall J, Hockaday A, Jaki T, Lowe R , Murphy C et al (2021) Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project. BMC Medicine, 19(1). View this article in WRRO
• Qian Y, Walters SJ, Jacques R & Flight L (2021) Comprehensive review of statistical methods for analysing patient-reported outcomes (PROs) used as primary outcomes in randomised controlled trials (RCTs) published by the UK’s Health Technology Assessment (HTA) journal (1997–2020). BMJ Open, 11(9). View this article in WRRO
• Hykin P, Prevost AT, Sivaprasad S, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Alshreef A, Flight L, Pennington R , Hounsome B et al (2021) Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technology Assessment, 25(83). View this article in WRRO
• Pennington R, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C , Kelly J et al (2021) Cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study. PharmacoEconomics.
• Pennington BM, Hernández-Alava M, Hykin P, Sivaprasad S, Flight L, Alshreef A & Brazier J (2020) Mapping from visual acuity to EQ-5D, EQ-5D with vision bolt-on, and VFQ-UI in patients with macular edema in the LEAVO trial. Value in Health. View this article in WRRO
• Flight L, Julious S, Brennan A, Todd S & Hind D (2020) How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis. Trials, 21(1). View this article in WRRO
• Flight L, Arshad F, Barnsley R, Patel K, Julious S, Brennan A & Todd S (2019) A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 22(4), 391-398. View this article in WRRO
• Candlish J, Teare MD, Dimairo M, Flight L, Mandefield L & Walters SJ (2018) Appropriate statistical methods for analysing partially nested randomised controlled trials with continuous outcomes: a simulation study.. BMC Medical Research Methodology, 18(1), 105-105. View this article in WRRO
• Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR , Villar SS et al (2018) Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine, 16. View this article in WRRO
• Flight L & Julious SA (2016) Corrections: The disagreeable behaviour of the kappa statistic. Pharmaceutical Statistics. View this article in WRRO
• Flight L, Allison A, Dimairo M, Lee E, Mandefield L & Walters SJ (2016) Recommendations for the analysis of individually randomised controlled trials with clustering in one arm – a case of continuous outcomes. BMC Medical Research Methodology, 16. View this article in WRRO
• Flight L, Julious SA & Goodacre S (2016) Can emergency medicine research benefit from adaptive design clinical trials?. Emergency Medicine Journal, 34, 243-248. View this article in WRRO
• Hatfield I, Allison A, Flight L, Julious SA & Dimairo M (2016) Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials, 17(1). View this article in WRRO
• Flight L & Julious SA (2016) Practical guide to sample size calculations: non-inferiority and equivalence trials. Pharmaceutical Statistics, 15(1), 80-89. View this article in WRRO
• Flight L & Julious SA (2016) Practical guide to sample size calculations: an introduction. Pharmaceutical Statistics, 15(1), 68-74. View this article in WRRO
• Flight L & Julious SA (2016) Practical guide to sample size calculations: superiority trials. Pharmaceutical Statistics, 15(1), 75-79. View this article in WRRO
• Flight L & Julious SA (2015) The disagreeable behaviour of the kappa statistic. Pharmaceutical Statistics, 14(1), 74-78.
• Pennington B, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C , Kelly J et al () Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. PharmacoEconomics.

Conference proceedings papers

• Flight L, Julious S, Brennan A & Todd S (2020) METHODS FOR CHOOSING THE BEST DESIGN OF A CLINICAL TRIAL: IMPLEMENTING EXPECTED VALUE OF SAMPLE INFORMATION AND ADJUSTING FOR BIAS INDUCED BY A GROUP SEQUENTIAL DESIGN. 41st Annual Meeting of the Society for Medical Decision Making Portland, Oregon, October 20–23, 2019, Vol. 40(1) (pp E1-E379)
• Pennington B, Alshreef A, Flight L, Hykin P, Sivaprasad S, Brazier JE & Hernández M (2019) PSS25 Mapping from visual acuity to utility in patients with macular oedema due to central retinal vein occlusion using data from the LEAVO trial. Value in Health, Vol. 22(Suppl. 3) (pp S891-S891). Copenhagen, Denmark, 2 November 2019 - 6 November 2019. View this article in WRRO
• Flight L, Alshreef A, Hykin PG, Sivaprasad S, Pennington B, Kelly J, Murphy CL & Brazier JE (2019) Intravitreal therapy with Ranibizumab vs Aflibercept vs Bevacizumab for macular oedema due to central retinal vein occlusion : a within trial cost-utility analysis. Value in Health, Vol. 22(Suppl 3) (pp S664-S664). Copenhagen, Denmark, 2 November 2019 - 6 November 2019. View this article in WRRO
• Flight L, Baxter S & Khan S (2019) Public involvement beyond clinical research studies. Trials, Vol. 20(Supplement 1) (pp 25-25). Brighton, UK, 6 October 2019 - 9 October 2019. View this article in WRRO
• Flight L, Hind D, Julious S, Brennan A & Todd S (2019) Considerations concerning the use of health economics in the design and analysis of adaptive clinical trials - a qualitative study. Trials, Vol. 20(Supplement 1) (pp 109-109). Brighton, UK, 6 October 2019 - 9 October 2019. View this article in WRRO

Reports

• Forster M, Flight L, Corbacho B, Keding A, Ronaldson S, Tharmanathan P, Welch C, Brennan A & Chick S (2021) Report for the EcoNomics of Adaptive Clinical Trials (ENACT) project: Application of a Bayesian Value-Based Sequential Model of a Clinical Trial to the CACTUS and HERO Case Studies (with Guidance Material for Clinical Trials Units) View this article in WRRO

Posters

• Candlish J, Teare D, Cohen J, Dimairo M, Flight L, Mandefield L & Walters S (2017) Methods to analyse partially nested randomised controlled trials.
• Walters S, Lee E, Flight L, Mandefield L, Dimario M & Allison A (2015) Analysis and reporting of individually randomised controlled trials with clustering in one arm only: how should we do it?.

Datasets

• Pennington R, Hernandez M, Hykin P, Sivaprasad S, Flight L, Alshreef A & Brazier J Utility calculator for visual acuity.

Preprints

• Robertson DS, Choodari-Oskooei B, Dimairo M, Flight L, Pallmann P & Jaki T (2021) Point estimation for adaptive trial designs, arXiv.
• Flight L, Brennan A, Chick SE, Forster M, Julious S & Tharmanathan P () Value-Adaptive Clinical Trial Designs for Efficient Delivery of Research – Actions, Opportunities and Challenges for Publicly Funded Trials. View this article in WRRO